Shades for Migraine Partners with Rising Influencers to Empower People with Migraine
May 25, 2021 09:03 ET
|
Association of Migraine Disorders
Rhode Island, May 25, 2021 (GLOBE NEWSWIRE) -- Providence, R.I. (May 25, 2021) – Global awareness campaign, Shades for Migraine®, teams up with two rising social media influencers, YouTuber,...
Trevena, Inc. to Participate at the Sachs Associates 4th Annual Neuroscience Innovation Forum
April 29, 2021 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central...
Aculief Reviews – Does this Migraine Relief Clip work? – Product Review by Mike Vaughn
January 24, 2021 23:57 ET
|
Mike Vaughn
New York, Jan. 24, 2021 (GLOBE NEWSWIRE) -- Lifestyle changes and styles, like working and using screens for long periods of time, have brought about migraines and headaches. Headaches can be such a...
Axsome Therapeutics Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatment of Migraine
December 31, 2020 06:00 ET
|
Axsome Therapeutics, Inc.
Over 21,000 migraine attacks treated with AXS-07 Achieved migraine pain relief in approximately 70% of patients, and pain freedom in approximately 40% of patients, at 2 hours Achieved...
Cerecin Enrolls First Patient in a Phase 2 Pilot Clinical Trial of Tricaprilin for Migraine Prevention (the Relief Study)
December 17, 2020 07:40 ET
|
Cerecin
Colorado, USA and Melbourne, Australia, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Cerecin, a biopharmaceutical company focused on brain therapeutics, announced the enrollment of the first patient in its...
Axsome Therapeutics and Veeva Systems Partner to Build Axsome’s Digital-Centric Commercialization™ Platform
November 04, 2020 07:03 ET
|
Axsome Therapeutics, Inc.
Collaboration provides Axsome access to new digital technologies developed by Veeva NEW YORK and PLEASANTON, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
Axsome Therapeutics Presents New Data from MOMENTUM Phase 3 Trial with AXS-07 Demonstrating Rapid Onset of Action and Reduced Symptom Recurrence in the Acute Treatment of Migraine
September 24, 2020 06:00 ET
|
Axsome Therapeutics, Inc.
Significantly faster time to pain relief as compared to rizatriptan (p<0.001) Significantly less relapse of migraine pain as compared to rizatriptan (p=0.001) Benefits demonstrated in...
Axsome Therapeutics Announces AXS-07 Phase 3 Migraine Trial Results Selected by the American Academy of Neurology Science Committee as Featured Presentation
September 17, 2020 07:00 ET
|
Axsome Therapeutics, Inc.
Data from MOMENTUM Phase 3 trial to be presented at the 2020 AAN Science Highlights Platform NEW YORK, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
Axsome Therapeutics Completes Successful FDA Pre-NDA Meeting for AXS-07 for the Acute Treatment of Migraine
August 20, 2020 07:00 ET
|
Axsome Therapeutics, Inc.
NDA submission on track for 4Q 2020 NEW YORK, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management...
Axsome Therapeutics to Report Second Quarter 2020 Financial Results on August 10, 2020
July 30, 2020 07:00 ET
|
Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Monday, August 10, 2020 at 8:00 AM Eastern Time NEW YORK, July 30, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...